The presence of double-positive CD43 and CD180, together with other B-cell surface markers, can improve the sensitivity of the diagnosis in CLL patients negative for CD5 or CD23 staining [63]. The gene discussed is FCER2; the disease is B-cell chronic lymphocytic leukemia.